This site is intended for health professionals only
Wednesday 22 May 2019
Share |

Industry News

Six in 10 pharmacy professionals in favour of banning homeopathy prescribing

Friday 7th September 2018

Six in 10 pharmacy professionals are against the sale and dispensing of homeopathic products, pharmacists at an international conference have heard.
In a congress session taking place at the International Pharmaceutical Federation’s (FIP) World Congress of Pharmacy and Pharmaceutical Science on Tuesday (4 September), 63% of between 150 to 200 people surveyed said ‘...

Thu, 14 May 2015
Jim O’Neills Review on Antimicrobial Resistance launches their third interim report. Amongst the report’s recommendations is the creation of a $2 billion global fund to be spent over five years to assist organisations pay for their R&D on developing new antibiotics. Grants will be awarded from this fund, which will delink the reward side of antibiotic drug development from sales and should incentivise organisations to get back into the antibiotic development space. Global fund monies will be used to finance blue skies research into new antibiotics and diagnostics and encourage innovative partnerships at early development stages between academia and industry.
Mon, 11 May 2015
This could help health service providers to better treat disease, control transmission of this infection, and monitor outbreaks. Tuberculosis (TB) disease rates in some parts of London are as high as in Sub-Saharan Africa, and drug-resistant strains are becoming increasingly common. These require specific treatments, and if doctors know that a bug is resistant they can start therapy earlier, often leading to better outcomes.
Wed, 6 May 2015
Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the oral suspension formulation and the 20mg capsule of Orfadin (nitisinone) for the treatment of hereditary tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated.
Tue, 5 May 2015
Bayer HealthCare reports that real-world data from a UK wide National Aflibercept Audit and Moorfields Aflibercept Audit have been presented at The Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting showcasing the efficacy of EYLEA® (aflibercept solution for injection) for the treatment of wet age-related macular degeneration (wAMD). The results from both audits highlight that treatment with aflibercept in NHS clinical practice has resulted in stabilised or improved visual and/or anatomical outcomes in treatment-naïve and pre-treated patients; (1–4) reflecting the results seen in the pivotal VIEW clinical trials. (5)
Wed, 29 Apr 2015
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen.
Tue, 28 Apr 2015
Genmab A/S announced that the top-line results from the Phase III COMPLEMENT 2 study showed that treatment with Arzerra® (ofatumumab) plus fludarabine and cyclophosphamide met the primary endpoint of improved progression-free survival (PFS) in patients with relapsed CLL (p=0.0036) compared to those given fludarabine and cyclophosphamide alone. The safety profile observed in this study was consistent with other trials of ofatumumab and no new safety signals were observed.
Mon, 27 Apr 2015
Bristol-Myers Squibb Company (BMS) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion in the European Union (EU) approving the ClickJect Pre-Filled Pen, a new autoinjector delivery device for ORENCIA (abatacept) for use in adult patients with moderate to severe active RA in combination with methotrexate after inadequate DMARD response. (1)

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher